Cargando…

ATRT-08. A PHASE II STUDY OF CONTINUOUS LOW DOSE PANOBINOSTAT IN PAEDIATRIC PATIENTS WITH MALIGNANT RHABDOID TUMORS/ATYPICAL TERATOID RHABDOID TUMORS

BACKGROUND: Panobinostat treatment has been shown to terminally differentiate malignant rhabdoid tumor (MRT)/atypical teratoid rhabdoid tumors (ATRT) in pre-clinical models. This is an open label, phase II study of panobinostat in patients with newly diagnosed or relapsed MRT/ATRT. AIMS: To assess t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wood, Paul, Desai, Jayesh, Waldeck, Kelly, Cain, Jason, Gottardo, Nick, Strong, Robyn, Kinross, Kathryn, Carr, Michelle, Jones, Janelle, Wong, Lily, Ziegler, David, Hansford, Jordan, Michael, Michael, Ashley, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Atypical Teratoid/Rhabdoid Tumors
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715339/ http://dx.doi.org/10.1093/neuonc/noaa222.008

Ejemplares similares

ATRT-17. A phase II study of continuous low dose panobinostat in paediatric patients with malignant rhabdoid tumours and atypical teratoid rhabdoid tumours.
por: Wood, Paul, et al.
Publicado: (2022)

ATRT-05. Infants and newborns with atypical teratoid/rhabdoid tumors (ATRT) and extracranial malignant rhabdoid tumors: a unique and challenging population
por: Nemes, Karolina, et al.
Publicado: (2022)

ATRT-21. RHABDOID PREDISPOSITION SYNDROME: REPORT OF MOLECULAR PROFILES AND TREATMENT APPROACH IN THREE CHILDREN WITH SYNCHRONOUS ATYPICAL TERATOID/RHABDOID TUMOR AND MALIGNANT RHABDOID TUMOR
por: Shatara, Margaret, et al.
Publicado: (2020)

ATRT-02. MEK/ERK SIGNALLING DEPENDENCY IN ATYPICAL TERATOID RHABDOID TUMOURS
por: Shi, Hui (Claire), et al.
Publicado: (2020)

ATRT-10. ATYPICAL TERATOID/RHABDOID TUMOR OF THE PINEAL REGION IN A PEDIATRIC PATIENT
por: Almeida, Carlos, et al.
Publicado: (2020)

ATRT-18. Atypical Teratoid/Rhabdoid Tumor in Children: Case Reports from Indonesia
por: Ramadhan, Diko Anugrah, et al.
Publicado: (2022)

ATRT-04. INHERITED RHABDOID PREDISPOSITION SYNDROME: A CASE OF CHOROID PLEXUS CARCINOMA AND ATYPICAL TERATOID RHABDOID TUMOR IN SIBLINGS
por: Judd, Alexis, et al.
Publicado: (2020)

ATRT-18. SHH-SUBTYPE ATYPICAL TERATOID/RHABDOID TUMORS ARE SELECTIVELY SENSITIVE TO GEMCITABINE TREATMENT
por: Metselaar, Dennis, et al.
Publicado: (2020)

ATRT-09. IDENTIFICATION OF HUB GENES IN ATYPICAL TERATOID/RHABDOID TUMORS BY MULTIPLE-MICROARRAY ANALYSIS
por: Liu, Wei, et al.
Publicado: (2020)

ATRT-07. DEFINING LOST AND GAINED TRANSCRIPTIONAL REGULATORY NETWORKS IN ATYPICAL TERATOID RHABDOID TUMOR
por: Nesvick, Cody, et al.
Publicado: (2021)

ATRT-26. META-ANALYSIS OF TREATMENT MODALITIES IN METASTATIC ATYPICAL TERATOID/RHABDOID TUMORS IN CHILDREN
por: Underiner, Reena M, et al.
Publicado: (2020)

ATRT-05. RESULTS OF MULTICENTER TRIAL CONCERNING THE TREATMENT OF CHILDREN WITH ATYPICAL TERATOID/RHABDOID TUMORS (ATRT) OF THE CENTRAL NERVOUS SYSTEM
por: Zheludkova, Olga, et al.
Publicado: (2020)

ATRT-07. HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION FOR AN ADULT PRESENTATION OF THE ATYPICAL TERATOID-RHABDOID TUMOR (ATRT)
por: Mrugala, Maciej, et al.
Publicado: (2020)

ATRT-06. Atypical Teratoid Rhabdoid Tumors (ATRT): results from a Single Institution in Brazil - São Paulo University
por: Barreto, Juliana Silveira, et al.
Publicado: (2022)

ATRT-30. RETROSPECTIVE ANALYSIS OF CHILDREN WITH ATYPICAL TERATOID RHABDOID TUMOR TREATED ACCORDING TO ACNS0333
por: Hoffman, Lindsey, et al.
Publicado: (2020)

ATRT-01. IDENTIFICATION OF MICRORNA-BASED PROGNOSTIC BIOMARKERS AND CANDIDATE THERAPEUTIC AGENTS FOR ATYPICAL TERATOID/RHABDOID TUMOR
por: Zhang, Yang
Publicado: (2021)

ATRT-06. SMARCB1 LOSS DRIVEN NON-CANONICAL PRC1 ACTIVITY REGULATES DIFFERENTIATION IN ATYPICAL TERATOID RHABDOID TUMORS (ATRT)
por: Alimova, Irina, et al.
Publicado: (2020)

ATRT-01. Reconstitution of cGAS/ STING pathway via epigenetic reprogramming leads to anti-viral inflammatory signaling in Atypical teratoid rhabdoid tumors (ATRTs)
por: Mangoli, Avani, et al.
Publicado: (2022)

ATRT-03. IDENTIFICATION OF microRNA-BASED PROGNOSTIC BIOMARKERS AND CANDIDATE THERAPEUTIC AGENTS FOR ATYPICAL TERATOID/RHABDOID TUMOR
por: Zhang, Yang, et al.
Publicado: (2020)

ATRT-02. Neuropsychological function in infant atypical teratoid/rhabdoid tumor versus low-grade glioma survivors reflects tumor malignancy and multimodal treatment
por: Traunwieser, Thomas, et al.
Publicado: (2022)

ATRT-01. UPREGULATION OF PROTEIN SYNTHESIS AND PROTEASOME DEGRADATION CONFERS SENSITIVITY TO PROTEASOME INHIBITOR BORTEZOMIB IN MYC-ATYPICAL TERATOID/RHABDOID TUMORS
por: Tran, Minh-Huy, et al.
Publicado: (2020)

ATRT-22. Outcomes for children with recurrent atypical teratoid rhabdoid tumor: A single institution study with updated molecular and germline analysis
por: Carey, Steven S, et al.
Publicado: (2022)

ATRT-22. HIGH-THROUGHPUT DRUG SCREENING OF FDA-APPROVED CANCER DRUGS REVEALS POTENTIAL THERAPEUTIC APPROACHES FOR ATYPICAL TERATOID RHABDOID TUMOUR
por: Chong, Wai Chin, et al.
Publicado: (2020)

ATRT-13. DIFFERENT CELLS OF ORIGIN PAVE THE WAY FOR MOLECULAR HETEROGENEITY IN RHABDOID TUMORS
por: Graf, Monika, et al.
Publicado: (2020)

ATRT-09. IDENTIFICATION OF POTENTIAL GENETIC DRIVERS OF METHOTREXATE (MTX) RESISTANCE IN ATYPICAL TERATOID RHABDOID TUMOURS (ATRT) THROUGH A GENOME-WIDE RNAI SCREEN
por: Kannappan, Sunand, et al.
Publicado: (2021)

ATRT-06. RESULTS OF MULTICENTER TRIAL CONCERNING THE TREATMENT OF CHILDREN WITH ATYPICAL TERATOID RHABDOID TUMORS OF THE CENTRAL NERVOUS SYSTEM UNDER 3 YEARS OLD
por: Olga, Zheludkova, et al.
Publicado: (2021)

ATRT-21. Contribution of germline mosaic alterations of SMARCB1 in rhabdoid tumor predisposition syndrome
por: Masliah-Planchon, Julien, et al.
Publicado: (2022)

ATRT-04. CORRELATION OF CLINICOPATHOLOGIC FEATURES AND CUMULATIVE INCIDENCE OF RELAPSE FOR PATIENTS WITH ATYPICAL TERATOID RHABDOID TUMOR ON ACNS0333: A REPORT FROM THE CHILDREN’S ONCOLOGY GROUP
por: Reddy, Alyssa, et al.
Publicado: (2021)

ATRT-11. PREVALENCE OF GERMLINE VARIANTS IN SMARCB1 INCLUDING SOMATIC MOSAICISM IN AT/RT AND OTHER RHABDOID TUMORS
por: Shirai, Ryota, et al.
Publicado: (2020)

ATRT-26. The PI3k inhibitor Paxalisib combines with the novel HDAC1/3 inhibitor RG2833 to improve survival in mice bearing orthotopic xenografts of atypical teratoid/rhabdoid tumors
por: Findlay, Tyler, et al.
Publicado: (2022)

ATRT-08. TARGETING THE TP53-MDM2 ENHANCES RADIATION SENSITIVITY IN ATRT
por: Alimova, Irina, et al.
Publicado: (2021)

ATRT-14. MACROPHAGE-TUMOR CELL INTERACTION PROMOTES ATRT PROGRESSION AND CHEMORESISTANCE
por: Melcher, Viktoria, et al.
Publicado: (2020)

ATRT-10. Single-cell transcriptional profiling of ATRTs reveals heterogeneous signatures of tumor and non-malignant cell populations
por: Blanco-Carmona, Enrique, et al.
Publicado: (2022)

ATRT-33. ENABLING RAPID CLASSIFICATION OF ATRT WITH NANOSTRING NCOUNTER PLATFORM
por: Ho, Ben, et al.
Publicado: (2020)

ATRT-27. COST-EFFECTIVE ASSAYS TO SUBGROUP ATRT IN THE DAILY ROUTINE
por: Lobon-Iglesias, María-Jesús, et al.
Publicado: (2020)

ATRT-07. Low-grade diffusely infiltrative tumor, SMARCB1-mutant: a clinical and histopathological distinct entity showing epigenetic similarity with ATRT-MYC
por: Thomas, Christian, et al.
Publicado: (2022)

ATRT-24. CELL SURFACE PROTEOME ANALYSIS OF ATRT IDENTIFIES TARGETS FOR IMMUNOTHERAPY
por: Cole, Allison, et al.
Publicado: (2020)

ATRT-13. An integrative analysis of the ATRT proteome unravels novel drug targets and refines molecular subgrouping
por: Johann, Pascal, et al.
Publicado: (2022)

ATRT-28. SINGLE NUCLEI SEQUENCING REVEALS THE DIFFERENT PHENOTYPIC COMPOSITION OF THE ATRT SUBGROUPS
por: Johann, Pascal, et al.
Publicado: (2020)

ATRT-19. Functional genomics reveal distinct modulators of response to CDK4/6 inhibitors in ATRTs
por: Merk, Daniel, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_f8cei79gd9mn8qdjtfniov0k4p